Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8624

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.38 USD +1.31% Intraday chart for Yield10 Bioscience, Inc. -12.56% +58.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada CI
North American Morning Briefing : Markets Steady -2- DJ
Top Midday Gainers MT
Yield10 Bioscience, Inc. Grants Global License to VISION Bioenergy Oilseeds, LLC for Herbicide Tolerant Camelina Cultivated for Production of Biofuel Feedstock CI
North American Morning Briefing : Stock Futures -2- DJ
Lake Street Downgrades Yield10 Bioscience to Hold From Buy, Cuts Price Target to $0.50 From $3 MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data MT
Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program CI
Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil CI
Transcript : Yield10 Bioscience, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Yield10 Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Yield10 Bioscience, Inc. Contemplates Bankruptcy. CI
Yield10 Bioscience, Inc. and Biomar Group Aim to Grow Fish Oil on Land CI
Yield10 Bioscience, Inc. Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Production Technology from Rothamsted Research CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Yield10 Bioscience Acquires License to Commercialize Advanced Omega-3 Technology MT
Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research CI
Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina CI
HC Wainwright Adjusts Price Target on Yield10 Bioscience to $4 From $25, Keeps Buy Rating MT
Transcript : Yield10 Bioscience, Inc., Q2 2023 Earnings Call, Aug 14, 2023
Yield10 Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Top Midday Decliners MT
Yield10 Bioscience Prices $3.7 Million Public Offering MT
Chart Yield10 Bioscience, Inc.
More charts
Yield10 Bioscience, Inc. is an agricultural bioscience company. The Company is using its differentiated trait gene discovery platform, the TraitFactory, to develop improved Camelina varieties for the production of seed products, and to discover high value genetic traits for the agriculture and food industries. The seed products include Camelina oil for use as a low carbon biofuel feedstock, Omega-3 oils for nutrition and PHA Bioplastics for biodegradable zero-waste packaging solutions. It is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low carbon sustainable seed products to address petroleum replacement markets, food and nutrition markets, and animal feed markets. It is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits. The Company's development pipeline falls into three categories: input traits, performance traits and new seed product traits.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.3751 USD
Average target price
0.5 USD
Spread / Average Target
+33.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Yield10 Bioscience, Inc. - Nasdaq
  4. News Yield10 Bioscience, Inc.
  5. Yield10 Bioscience Signs MOU With Mitsubishi for Biofuel Partnership; Shares Jump Thursday